Aceprobe

Founded: 2009 • Age: 17 yrs
Healthcare services involving diagnostics, therapy, and biotechnology innovations.
Request Access
Report Incorrect Data
Annual revenue $442,488 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Aceprobe

Aceprobe is a company founded in 2009. Aceprobe offers products and services including Oncology Consult and Cancer Immunotherapy.

Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research → Unlock Sub-Sector → Unlock Segment
Healthcare → Healthcare Products & Supplies → Unlock Sub-Sector → Unlock Segment
Key Metrics
  • Annual Revenue
    $442.49 K (USD)
    283.35
    as on Mar 31, 2023
  • Net Profit
    $8.24 K (USD)
    846.99
    as on Mar 31, 2023
  • EBITDA
    $42.36 K (USD)
    181.73
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Aceprobe

Aceprobe offers a comprehensive portfolio of products and services, including Oncology Consult and Cancer Immunotherapy.

Product name locked
Category locked
Primary

Second opinions and expert advice for oncology are provided to support treatment plans and rare toxicity management.

Product name locked
Category locked
Locked

CAR-T Cell Therapy is offered as a one-time infusion to recognize and attack cancer cells.

Funding Insights of Aceprobe

Premium access

Detailed funding history for Aceprobe

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Aceprobe

Investments
Premium access

Investment portfolio details for Aceprobe

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Aceprobe

Premium access

Detailed financials for Aceprobe

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Aceprobe Comparisons

Aceprobe Primary company
Description
Healthcare services involving diagnostics, therapy, and biot...
Location
-
Founded Year
2009
Annual Revenue
$442.49 K (USD)
Net Profit
$8.24 K (USD)
EBITDA
$42.36 K (USD)
Employees
Not available
Premium access

Peer comparison for Aceprobe

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Aceprobe

Premium access

Detailed competitors of Aceprobe

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Aceprobe

Premium access

Complete news archive for Aceprobe

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aceprobe

Aceprobe was founded in 2009.

Annual revenue of Aceprobe is $442.49K as on Mar 31, 2023.

Lives are helped to be explained, mended, and transformed through a fusion of Biomedicine and Biotechnology by Aceprobe. Futuristic healthcare is embraced to achieve Precision Medicine via personal, digital, and functional approaches, while commitment is maintained to the changing needs of clients and the industry. A two-way model ensures equal participation between seekers and providers, guiding clinical decisions with proven expertise in Healthcare Innovations. Biotechnological sciences, regenerative medicine, and neurosciences are traced within the 21st-century economy to secure everyday life, with products and services aiding therapeutic decisions.

Aceprobe offers Oncology Consult and Cancer Immunotherapy.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available